The stable group and the progression group had no significant differences in terms of mean age, frequencies of ApoE ε4 carriers, median education level, median BMI, frequencies of a smoking history, antiplatelet drug use, antithrombotic drug use, a family history of stroke, and frequencies of comorbidities such as hypertension, diabetes mellitus, hypercholesterolemia, and atrial fibrillation. The gene discussed is APOE; the disease is familial hypercholesterolemia.